Skip to main content

Table 5 Neurologic diseases treated with both intravenous immunoglobulin infusion and therapeutic plasma exchange

From: Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome

Neurologic Disease Role of intravenous immunoglobulin infusion in treatment [33] Role of therapeutic plasma exchange in treatment [13]
Acute inflammatory demyelinating polyneuropathy (AIDP, Guillain-Barré syndrome) Definite First line therapy with a strong recommendation and high-quality evidence. (Category I, Recommendation grade 1A)
Chronic inflammatory demyelinating polyneuropathy (CIDP) Definite First line therapy with a strong recommendation and moderate quality evidence. (Category I, Recommendation grade 1B)
Lambert-Eaton myasthenic syndrome (LEMS) Probable Second line therapy with a weak recommendation and low quality or very low quality evidence. (Category II, Recommendation grade 2C)
IgM anti-myelin associated glycoprotein paraprotein associated peripheral neuropathy Probable First line therapy with a strong recommendation and low quality or very low quality evidence. (Category I, Recommendation grade 1C)
Myasthenia gravis (MG) Probable First line therapy with a strong recommendation and high-quality evidence. (Category I, Recommendation grade 1A)
Multiple sclerosis (MS) Possible Second line therapy with a strong recommendation and moderate quality evidence. (Category II, Recommendation grade 1B)
Acute disseminated encephalomyelitis (ADEM) Possible Second line therapy with a weak recommendation and moderate quality evidence. (Category II, Recommendation grade 2C)